SurVaxM Expanded Access Protocol

Data from clinical trials suggest that SurVaxM administered as a single agent, or in combination with standard glioblastoma chemotherapy treatment regimens to patients with recurrent or newly diagnosed glioblastoma, is generally well tolerated and may increase progression free survival and overall survival in some patients

Expanded Access to SurVaxM for Treatment of Patients with Glioblastoma Who Have No Access to Other Comparable or Alternative Therapy or Have Completed Treatment on a non-Randomized Clinical Trial of SurVaxM and May Benefit from Further Treatment